{"output": [["bluebird bio Inc", "COMP", "Announce", "three novel treatments", "PRODUCT"], ["bluebird bio Inc", "COMP", "Expects_To_File_For_Approval", "treatment for transfusion-dependent beta thalassemia", "PRODUCT"], ["bluebird bio Inc", "COMP", "Operate_In", "Biotech sector", "SECTOR"], ["bluebird bio Inc", "COMP", "Develop", "CAR-T therapy for multiple myeloma", "PRODUCT", "with", "Celgene Corp", "COMP"], ["bluebird bio Inc", "COMP", "Develop", "treatment for cerebral adrenoleukodystrophy", "PRODUCT"], ["bluebird bio Inc", "COMP", "Cause", "stir", "EVENT", "at", "American Society of Hematology meeting", "EVENT"], ["bluebird bio Inc", "COMP", "Expects_To_File_For_U_S_and_European_Approval", "bb2121", "PRODUCT"], ["bluebird bio Inc", "COMP", "Develop", "promising treatment for sickle cell disease", "PRODUCT"], ["bluebird bio Inc", "COMP", "Plan", "discuss", "appropriate endpoints", "CONCEPT", "for future sickle cell clinical trials", "EVENT", "with", "health regulators", "ORG/REG"], ["bluebird bio Inc", "COMP", "Looking_To_Develop", "right pricing and reimbursement strategy", "CONCEPT", "for treatments", "PRODUCT"], ["Novartis", "COMP", "Price", "$475,000", "ECON_INDICATOR", "for CAR-T treatment", "PRODUCT"], ["Gilead Sciences", "COMP", "Price", "$373,000", "ECON_INDICATOR", "for CAR-T treatment", "PRODUCT"]], "published": "2018-01-09T20:44:00.000+02:00"}